PL3412277T3 - Preparaty proszkowe zawierające kortykosteroid i środek beta-adrenergiczny do podawania wziewnego - Google Patents

Preparaty proszkowe zawierające kortykosteroid i środek beta-adrenergiczny do podawania wziewnego

Info

Publication number
PL3412277T3
PL3412277T3 PL18181331.2T PL18181331T PL3412277T3 PL 3412277 T3 PL3412277 T3 PL 3412277T3 PL 18181331 T PL18181331 T PL 18181331T PL 3412277 T3 PL3412277 T3 PL 3412277T3
Authority
PL
Poland
Prior art keywords
corticosteroid
adrenergic
inhalation
beta
administration
Prior art date
Application number
PL18181331.2T
Other languages
English (en)
Inventor
Elisa MONARI
Anna Maria Cantarelli
Daniela Cocconi
Irene PASQUALI
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3412277(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of PL3412277T3 publication Critical patent/PL3412277T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0003—Details of inhalators; Constructional features thereof with means for dispensing more than one drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL18181331.2T 2012-01-25 2013-01-23 Preparaty proszkowe zawierające kortykosteroid i środek beta-adrenergiczny do podawania wziewnego PL3412277T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12152392 2012-01-25

Publications (1)

Publication Number Publication Date
PL3412277T3 true PL3412277T3 (pl) 2023-06-19

Family

ID=47715987

Family Applications (6)

Application Number Title Priority Date Filing Date
PL18181331.2T PL3412277T3 (pl) 2012-01-25 2013-01-23 Preparaty proszkowe zawierające kortykosteroid i środek beta-adrenergiczny do podawania wziewnego
PL19167835.8T PL3527198T3 (pl) 2012-01-25 2013-01-23 Preparaty proszkowe zawierające kortykosteroid i środek beta-adrenergiczny do podawania wziewnego
PL19167775.6T PL3527196T3 (pl) 2012-01-25 2013-01-23 Preparat suchego proszku zawierający kortykosteroid i środek beta-adrenergiczny do podawania przez inhalację
PL19167839.0T PL3527199T3 (pl) 2012-01-25 2013-01-23 Preparat suchego proszku zawierający kortykosteroid i środek beta-adrenergiczny do podawania przez inhalację
PL13704372T PL2806855T3 (pl) 2012-01-25 2013-01-23 Preparaty proszkowe, zawierające kortykosteroid i środek beta-adrenergiczny do podawania wziewnego
PL19167829.1T PL3527197T3 (pl) 2012-01-25 2013-01-23 Preparat suchego proszku zawierający kortykosteroid i środek beta-adrenergiczny do podawania przez inhalację

Family Applications After (5)

Application Number Title Priority Date Filing Date
PL19167835.8T PL3527198T3 (pl) 2012-01-25 2013-01-23 Preparaty proszkowe zawierające kortykosteroid i środek beta-adrenergiczny do podawania wziewnego
PL19167775.6T PL3527196T3 (pl) 2012-01-25 2013-01-23 Preparat suchego proszku zawierający kortykosteroid i środek beta-adrenergiczny do podawania przez inhalację
PL19167839.0T PL3527199T3 (pl) 2012-01-25 2013-01-23 Preparat suchego proszku zawierający kortykosteroid i środek beta-adrenergiczny do podawania przez inhalację
PL13704372T PL2806855T3 (pl) 2012-01-25 2013-01-23 Preparaty proszkowe, zawierające kortykosteroid i środek beta-adrenergiczny do podawania wziewnego
PL19167829.1T PL3527197T3 (pl) 2012-01-25 2013-01-23 Preparat suchego proszku zawierający kortykosteroid i środek beta-adrenergiczny do podawania przez inhalację

Country Status (37)

Country Link
US (3) US10028964B2 (pl)
EP (7) EP3527199B1 (pl)
JP (1) JP6104282B2 (pl)
KR (3) KR101786586B1 (pl)
CN (2) CN104080444B (pl)
AR (1) AR089805A1 (pl)
AU (1) AU2013211656B2 (pl)
BR (1) BR112014017481A8 (pl)
CA (1) CA2862548C (pl)
CL (1) CL2014001966A1 (pl)
CO (1) CO7010836A2 (pl)
CY (3) CY1120684T1 (pl)
DK (6) DK3527196T3 (pl)
EA (2) EA026267B1 (pl)
ES (6) ES2683254T3 (pl)
FI (2) FI3412277T3 (pl)
GE (1) GEP201706767B (pl)
HR (6) HRP20221431T1 (pl)
HU (6) HUE060421T2 (pl)
IL (1) IL233784A0 (pl)
LT (5) LT3527197T (pl)
MA (1) MA35859B1 (pl)
MX (2) MX355729B (pl)
MY (1) MY165888A (pl)
NZ (1) NZ627837A (pl)
PE (1) PE20141703A1 (pl)
PH (1) PH12014501565B1 (pl)
PL (6) PL3412277T3 (pl)
PT (6) PT3527198T (pl)
RS (5) RS57637B1 (pl)
SG (1) SG11201404350PA (pl)
SI (3) SI2806855T1 (pl)
TN (1) TN2014000322A1 (pl)
TW (1) TWI559940B (pl)
UA (1) UA115543C2 (pl)
WO (1) WO2013110632A1 (pl)
ZA (1) ZA201405464B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013211656B2 (en) * 2012-01-25 2017-07-13 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
HUE053957T2 (hu) 2013-07-11 2021-08-30 Chiesi Farm Spa Antikolinerg, kortikoszteroid és béta-adrenerg anyagot tartalmazó száraz porkészítmény inhalálással történõ beadásra
UA118861C2 (uk) * 2013-12-06 2019-03-25 Оріон Корпорейшн Спосіб отримання сухих порошкових композицій для інгаляцій
JP6919093B2 (ja) 2014-10-08 2021-08-18 ザンボン ソシエタ ペル アチオニ 配合物の安定性を高めるために噴霧乾燥によって得られる少なくとも１種の乾燥粉末を含む組成物
CN109789107B (zh) * 2016-09-29 2021-12-03 广东东阳光药业有限公司 药物组合物
CA3060020A1 (en) * 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2019067866A1 (en) * 2017-09-29 2019-04-04 Crititech, Inc. GLUCOCORTICOID PARTICLES AND THEIR USE
ES2953293T3 (es) * 2018-08-07 2023-11-10 Norton Waterford Ltd Aplicación de espectroscopia Raman para la fabricación de polvos para inhalación
EP3873574B1 (en) 2018-10-30 2023-12-06 Chiesi Farmaceutici S.p.A. Apparatus to administer drugs to mechanically ventilated patients
BR112022004970A2 (pt) 2019-09-24 2022-08-23 Chiesi Farm Spa Formulação de pó seco, processo para preparar uma formulação de pó seco e inalador de pó seco
MX2023001875A (es) 2020-08-14 2023-06-29 Norton Waterford Ltd Formulación inhalable de propionato de fluticasona y sulfato de albuterol.
WO2023117967A1 (en) * 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
AU756852B2 (en) * 1998-11-13 2003-01-23 Jagotec Ag Dry powder for inhalation
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
EP1658872B2 (en) 2002-07-31 2019-08-21 CHIESI FARMACEUTICI S.p.A. Powder inhaler
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
EP1944018A1 (en) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
GB0914240D0 (en) * 2009-08-14 2009-09-30 Breath Ltd Steroid solvates
RS53514B1 (sr) * 2009-10-02 2015-02-27 Chiesi Farmaceutici S.P.A. Farmaceutske aerosolne formulacije od formoterola i beklometazon dipropionata
BR112012024059B1 (pt) * 2010-04-01 2021-06-01 Chiesi Farmaceutici S.P.A. Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco
WO2011131663A1 (en) 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. "process for providing particles with reduced electrostatic charges"
AU2013211656B2 (en) * 2012-01-25 2017-07-13 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
HUE053957T2 (hu) * 2013-07-11 2021-08-30 Chiesi Farm Spa Antikolinerg, kortikoszteroid és béta-adrenerg anyagot tartalmazó száraz porkészítmény inhalálással történõ beadásra

Also Published As

Publication number Publication date
EP3527198B1 (en) 2024-10-09
AU2013211656B2 (en) 2017-07-13
HRP20241638T1 (hr) 2025-02-14
DK3527197T3 (da) 2022-10-24
EP3412277B1 (en) 2022-12-14
NZ627837A (en) 2016-04-29
SI3527198T1 (sl) 2025-03-31
CN105726548A (zh) 2016-07-06
KR20150089093A (ko) 2015-08-04
ES2938466T3 (es) 2023-04-11
LT3527196T (lt) 2022-11-25
DK3527196T3 (da) 2022-10-24
UA115543C2 (uk) 2017-11-27
US10946029B2 (en) 2021-03-16
PT3527198T (pt) 2024-12-04
PL3527196T3 (pl) 2022-11-21
EP2806855B1 (en) 2018-07-11
WO2013110632A1 (en) 2013-08-01
CO7010836A2 (es) 2014-07-31
KR101560288B1 (ko) 2015-10-14
TW201334810A (zh) 2013-09-01
HRP20181550T1 (hr) 2018-11-30
PL3527197T3 (pl) 2022-11-21
LT2806855T (lt) 2018-10-10
EP3527197B1 (en) 2022-09-07
TN2014000322A1 (en) 2015-12-21
LT3527199T (lt) 2022-12-12
ES2996893T3 (en) 2025-02-13
HUE040525T2 (hu) 2019-03-28
CY1125595T1 (el) 2026-02-25
SI3412277T1 (sl) 2023-03-31
AU2013211656A1 (en) 2014-07-24
JP2015508416A (ja) 2015-03-19
CN104080444A (zh) 2014-10-01
RS63952B1 (sr) 2023-02-28
HK1200021A1 (en) 2015-07-31
BR112014017481A2 (pt) 2017-06-13
RS63759B1 (sr) 2022-12-30
HRP20221431T1 (hr) 2023-01-06
PL3527199T3 (pl) 2022-12-12
BR112014017481A8 (pt) 2021-06-15
ES2929807T3 (es) 2022-12-01
AR089805A1 (es) 2014-09-17
CY1125579T1 (el) 2026-02-25
EA201690187A1 (ru) 2016-05-31
EA031566B1 (ru) 2019-01-31
US8778402B2 (en) 2014-07-15
ES2929137T3 (es) 2022-11-25
IL233784A0 (en) 2014-09-30
RS57637B1 (sr) 2018-11-30
EP3527199A1 (en) 2019-08-21
HRP20221433T1 (hr) 2023-01-06
US20180296573A1 (en) 2018-10-18
EP3412277A1 (en) 2018-12-12
PT2806855T (pt) 2018-09-28
JP6104282B2 (ja) 2017-03-29
MA35859B1 (fr) 2014-12-01
RS63761B1 (sr) 2022-12-30
KR20170116234A (ko) 2017-10-18
EP3527197A1 (en) 2019-08-21
DK3527198T3 (da) 2024-10-28
PT3527197T (pt) 2022-10-26
HUE060402T2 (hu) 2023-02-28
HUE060421T2 (hu) 2023-02-28
SG11201404350PA (en) 2014-08-28
MY165888A (en) 2018-05-18
PT3412277T (pt) 2023-02-14
CN105726548B (zh) 2019-05-14
US10028964B2 (en) 2018-07-24
HRP20221432T1 (hr) 2023-01-06
FI3527198T3 (fi) 2024-12-13
EP3527196B1 (en) 2022-09-07
ES2928688T3 (es) 2022-11-22
EP2806855A1 (en) 2014-12-03
FI3412277T3 (fi) 2023-03-23
HUE061566T2 (hu) 2023-07-28
HUE069624T2 (hu) 2025-03-28
HRP20230147T1 (hr) 2023-03-31
PT3527199T (pt) 2022-11-08
PT3527196T (pt) 2022-10-18
CA2862548C (en) 2020-07-07
MX355729B (es) 2018-04-27
RS63706B1 (sr) 2022-11-30
US20130189324A1 (en) 2013-07-25
GEP201706767B (en) 2017-11-10
EP3527198A1 (en) 2019-08-21
PL3527198T3 (pl) 2025-01-27
KR20140114374A (ko) 2014-09-26
EA201491281A1 (ru) 2014-12-30
LT3412277T (lt) 2023-04-25
MX368199B (es) 2019-09-24
CL2014001966A1 (es) 2014-11-14
PH12014501565A1 (en) 2014-10-08
PH12014501565B1 (en) 2014-10-08
DK3412277T3 (da) 2023-02-20
LT3527197T (lt) 2022-11-25
ES2683254T3 (es) 2018-09-25
EA026267B1 (ru) 2017-03-31
EP3527199B1 (en) 2022-09-07
US20150164915A1 (en) 2015-06-18
CN104080444B (zh) 2017-06-20
DK3527199T3 (da) 2022-10-24
KR101786586B1 (ko) 2017-10-18
EP3527196A1 (en) 2019-08-21
PE20141703A1 (es) 2014-11-24
SI2806855T1 (sl) 2018-11-30
EP3020394A1 (en) 2016-05-18
TWI559940B (en) 2016-12-01
PL2806855T3 (pl) 2018-12-31
CY1120684T1 (el) 2019-12-11
ZA201405464B (en) 2015-12-23
KR101895279B1 (ko) 2018-09-05
HUE060705T2 (hu) 2023-04-28
DK2806855T3 (en) 2018-09-03
CA2862548A1 (en) 2013-08-01
MX2014008631A (es) 2014-08-21

Similar Documents

Publication Publication Date Title
TWI559940B (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
IL243507A0 (en) A dry powder formulation containing an anticholinergic agent, a steroid and an adrenergic agent for inhalation administration
HUE042757T2 (hu) Szállító szert tartalmazó készítmények és elõállításuk
ZA201308905B (en) Nasal pharmaceutical formulation comprising fluticasone
IL227651A (en) Topical pharmacological formulations containing 220b
PT3409270T (pt) Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação